Interactions of pyridostigmine with cardiopulmonary systems and their relationships to plasma cholinesterase activity

Robert William Caldwell, Howard S. Lowensohn, Mary A. Chryssanthis, Clinton B. Nash

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Interactions of Pyridostigmine with Cardiopulmonary Systems and Their Relationships to Plasma Cholinesterase Activity. CALDWELL, R. W., LOWENSOHN, H. S., CHRYSSANTHIS, M. A., AND NASH, C. B. (1989). Fundam Appl. Toxicol. 12, 432-441. Three dose levels of pyridostigmine (0.5,2, and 5 mg/kg) were given iv to dogs anesthetized with sodium pentobarbi tal. Hemodynamic measurements made were cardiac output, blood pressure, left ventricular dP/dT, and heart rate. Pulmonary function data obtained were airway resistance, respiratory rate, and tidal volume. Activity of blood cholinesterase was also measured. Increasing doses of pyridostigmine promptly and progressively lowered the acetylcholinesterase activity of blood to a minimum of 40% of control at the 5 mg%kg dose. Airway resistance was most sensitive to the drug. Resistance increased significantly with 2 mg/kg, and the 5 mg/kg dose resulted in more than a 10-fold increase, which persisted for more than 2 hr. Tidal volume was decreased and minute volume was increased due to an increase in respiratory rate. With the higher doses, heart rate decreased and stroke volume rose sufficiently to compensate so that cardiac output was unchanged. The lowest dose produced minimal effects on both cardiovascular and respiratory systems, and since this dose is greater than that proposed for organophosphate poisoning in humans, it seems likely that this drug would not cause important effects in normal humans when used as a protective agent.

Original languageEnglish (US)
Pages (from-to)432-441
Number of pages10
JournalToxicological Sciences
Volume12
Issue number3
DOIs
StatePublished - Apr 1 1989
Externally publishedYes

Fingerprint

Pyridostigmine Bromide
Cholinesterases
Airway Resistance
Tidal Volume
Respiratory Rate
Plasmas
Cardiac Output
Blood
Heart Rate
Organophosphate Poisoning
Respiratory system
Protective Agents
Cardiovascular system
Organophosphates
Blood pressure
Hemodynamics
Beam plasma interactions
Acetylcholinesterase
Cardiovascular System
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Toxicology

Cite this

Interactions of pyridostigmine with cardiopulmonary systems and their relationships to plasma cholinesterase activity. / Caldwell, Robert William; Lowensohn, Howard S.; Chryssanthis, Mary A.; Nash, Clinton B.

In: Toxicological Sciences, Vol. 12, No. 3, 01.04.1989, p. 432-441.

Research output: Contribution to journalArticle

Caldwell, Robert William ; Lowensohn, Howard S. ; Chryssanthis, Mary A. ; Nash, Clinton B. / Interactions of pyridostigmine with cardiopulmonary systems and their relationships to plasma cholinesterase activity. In: Toxicological Sciences. 1989 ; Vol. 12, No. 3. pp. 432-441.
@article{d6ad2ca2a6434c14859b29db7dc01f48,
title = "Interactions of pyridostigmine with cardiopulmonary systems and their relationships to plasma cholinesterase activity",
abstract = "Interactions of Pyridostigmine with Cardiopulmonary Systems and Their Relationships to Plasma Cholinesterase Activity. CALDWELL, R. W., LOWENSOHN, H. S., CHRYSSANTHIS, M. A., AND NASH, C. B. (1989). Fundam Appl. Toxicol. 12, 432-441. Three dose levels of pyridostigmine (0.5,2, and 5 mg/kg) were given iv to dogs anesthetized with sodium pentobarbi tal. Hemodynamic measurements made were cardiac output, blood pressure, left ventricular dP/dT, and heart rate. Pulmonary function data obtained were airway resistance, respiratory rate, and tidal volume. Activity of blood cholinesterase was also measured. Increasing doses of pyridostigmine promptly and progressively lowered the acetylcholinesterase activity of blood to a minimum of 40{\%} of control at the 5 mg{\%}kg dose. Airway resistance was most sensitive to the drug. Resistance increased significantly with 2 mg/kg, and the 5 mg/kg dose resulted in more than a 10-fold increase, which persisted for more than 2 hr. Tidal volume was decreased and minute volume was increased due to an increase in respiratory rate. With the higher doses, heart rate decreased and stroke volume rose sufficiently to compensate so that cardiac output was unchanged. The lowest dose produced minimal effects on both cardiovascular and respiratory systems, and since this dose is greater than that proposed for organophosphate poisoning in humans, it seems likely that this drug would not cause important effects in normal humans when used as a protective agent.",
author = "Caldwell, {Robert William} and Lowensohn, {Howard S.} and Chryssanthis, {Mary A.} and Nash, {Clinton B.}",
year = "1989",
month = "4",
day = "1",
doi = "10.1093/toxsci/12.3.432",
language = "English (US)",
volume = "12",
pages = "432--441",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Interactions of pyridostigmine with cardiopulmonary systems and their relationships to plasma cholinesterase activity

AU - Caldwell, Robert William

AU - Lowensohn, Howard S.

AU - Chryssanthis, Mary A.

AU - Nash, Clinton B.

PY - 1989/4/1

Y1 - 1989/4/1

N2 - Interactions of Pyridostigmine with Cardiopulmonary Systems and Their Relationships to Plasma Cholinesterase Activity. CALDWELL, R. W., LOWENSOHN, H. S., CHRYSSANTHIS, M. A., AND NASH, C. B. (1989). Fundam Appl. Toxicol. 12, 432-441. Three dose levels of pyridostigmine (0.5,2, and 5 mg/kg) were given iv to dogs anesthetized with sodium pentobarbi tal. Hemodynamic measurements made were cardiac output, blood pressure, left ventricular dP/dT, and heart rate. Pulmonary function data obtained were airway resistance, respiratory rate, and tidal volume. Activity of blood cholinesterase was also measured. Increasing doses of pyridostigmine promptly and progressively lowered the acetylcholinesterase activity of blood to a minimum of 40% of control at the 5 mg%kg dose. Airway resistance was most sensitive to the drug. Resistance increased significantly with 2 mg/kg, and the 5 mg/kg dose resulted in more than a 10-fold increase, which persisted for more than 2 hr. Tidal volume was decreased and minute volume was increased due to an increase in respiratory rate. With the higher doses, heart rate decreased and stroke volume rose sufficiently to compensate so that cardiac output was unchanged. The lowest dose produced minimal effects on both cardiovascular and respiratory systems, and since this dose is greater than that proposed for organophosphate poisoning in humans, it seems likely that this drug would not cause important effects in normal humans when used as a protective agent.

AB - Interactions of Pyridostigmine with Cardiopulmonary Systems and Their Relationships to Plasma Cholinesterase Activity. CALDWELL, R. W., LOWENSOHN, H. S., CHRYSSANTHIS, M. A., AND NASH, C. B. (1989). Fundam Appl. Toxicol. 12, 432-441. Three dose levels of pyridostigmine (0.5,2, and 5 mg/kg) were given iv to dogs anesthetized with sodium pentobarbi tal. Hemodynamic measurements made were cardiac output, blood pressure, left ventricular dP/dT, and heart rate. Pulmonary function data obtained were airway resistance, respiratory rate, and tidal volume. Activity of blood cholinesterase was also measured. Increasing doses of pyridostigmine promptly and progressively lowered the acetylcholinesterase activity of blood to a minimum of 40% of control at the 5 mg%kg dose. Airway resistance was most sensitive to the drug. Resistance increased significantly with 2 mg/kg, and the 5 mg/kg dose resulted in more than a 10-fold increase, which persisted for more than 2 hr. Tidal volume was decreased and minute volume was increased due to an increase in respiratory rate. With the higher doses, heart rate decreased and stroke volume rose sufficiently to compensate so that cardiac output was unchanged. The lowest dose produced minimal effects on both cardiovascular and respiratory systems, and since this dose is greater than that proposed for organophosphate poisoning in humans, it seems likely that this drug would not cause important effects in normal humans when used as a protective agent.

UR - http://www.scopus.com/inward/record.url?scp=77957183161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957183161&partnerID=8YFLogxK

U2 - 10.1093/toxsci/12.3.432

DO - 10.1093/toxsci/12.3.432

M3 - Article

C2 - 2731658

AN - SCOPUS:77957183161

VL - 12

SP - 432

EP - 441

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 3

ER -